106 related articles for article (PubMed ID: 9533440)
1. A three-dimensional model of the Fas/APO-1 molecule: cross-reactivity of anti-Fas antibodies explained by structural mimicry of antigenic sites.
Fadeel B; Lindberg J; Achour A; Chiodi F
Int Immunol; 1998 Feb; 10(2):131-40. PubMed ID: 9533440
[TBL] [Abstract][Full Text] [Related]
2. Mapping of the linear site on the Fas/APO-1 molecule targeted by the prototypic anti-Fas mAb.
Fadeel B; Thorpe J; Chiodi F
Int Immunol; 1995 Dec; 7(12):1967-75. PubMed ID: 8746566
[TBL] [Abstract][Full Text] [Related]
3. Humanization and epitope mapping of neutralizing anti-human Fas ligand monoclonal antibodies: structural insights into Fas/Fas ligand interaction.
Nisihara T; Ushio Y; Higuchi H; Kayagaki N; Yamaguchi N; Soejima K; Matsuo S; Maeda H; Eda Y; Okumura K; Yagita H
J Immunol; 2001 Sep; 167(6):3266-75. PubMed ID: 11544314
[TBL] [Abstract][Full Text] [Related]
4. Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro.
Fadeel B; Thorpe CJ; Yonehara S; Chiodi F
Int Immunol; 1997 Feb; 9(2):201-9. PubMed ID: 9040002
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of an eight amino acid domain shared by Fas (CD95/Apo-I) and HIV-1 gp120. I. Structural and antigenic analysis.
Silvestris F; Cocco T; Cafforio P; Calvani N; Dammacco F
Mol Med; 2000 Jun; 6(6):494-508. PubMed ID: 10972086
[TBL] [Abstract][Full Text] [Related]
6. Prediction of the three-dimensional structure of the human Fas receptor by comparative molecular modeling.
Bajorath J; Aruffo A
J Comput Aided Mol Des; 1997 Jan; 11(1):3-8. PubMed ID: 9139110
[TBL] [Abstract][Full Text] [Related]
7. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.
Oehm A; Behrmann I; Falk W; Pawlita M; Maier G; Klas C; Li-Weber M; Richards S; Dhein J; Trauth BC
J Biol Chem; 1992 May; 267(15):10709-15. PubMed ID: 1375228
[TBL] [Abstract][Full Text] [Related]
8. Combination of molecular mimicry and aberrant autoantigen expression is important for development of anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
Mihara S; Suzuki N; Takeba Y; Soejima K; Yamamoto S
Clin Exp Immunol; 2002 Aug; 129(2):359-69. PubMed ID: 12165095
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.
Pitti RM; Marsters SA; Ruppert S; Donahue CJ; Moore A; Ashkenazi A
J Biol Chem; 1996 May; 271(22):12687-90. PubMed ID: 8663110
[TBL] [Abstract][Full Text] [Related]
10. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway.
Schattner EJ; Elkon KB; Yoo DH; Tumang J; Krammer PH; Crow MK; Friedman SM
J Exp Med; 1995 Nov; 182(5):1557-65. PubMed ID: 7595225
[TBL] [Abstract][Full Text] [Related]
11. Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death.
Schulze-Osthoff K; Krammer PH; Dröge W
EMBO J; 1994 Oct; 13(19):4587-96. PubMed ID: 7523113
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship of the p55 TNF receptor death domain and its lymphoproliferation mutants.
De Wilde G; Murray-Rust J; Boone E; Olerenshaw D; McDonald NQ; Ibanez C; Haegeman G; Wollmer A; Federwisch M
Eur J Biochem; 2001 Mar; 268(5):1382-91. PubMed ID: 11231290
[TBL] [Abstract][Full Text] [Related]
13. A region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR-I and Fas.
Chapman BS
FEBS Lett; 1995 Oct; 374(2):216-20. PubMed ID: 7589538
[TBL] [Abstract][Full Text] [Related]
14. Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively.
Kajiwara K; Saito A; Ogata S; Tanihara M
Biochim Biophys Acta; 2004 Jun; 1699(1-2):131-7. PubMed ID: 15158720
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.
Schneider P; Bodmer JL; Holler N; Mattmann C; Scuderi P; Terskikh A; Peitsch MC; Tschopp J
J Biol Chem; 1997 Jul; 272(30):18827-33. PubMed ID: 9228058
[TBL] [Abstract][Full Text] [Related]
16. Segregation of APO-1/Fas antigen- and tumor necrosis factor receptor-mediated apoptosis.
Grell M; Krammer PH; Scheurich P
Eur J Immunol; 1994 Oct; 24(10):2563-6. PubMed ID: 7523147
[TBL] [Abstract][Full Text] [Related]
17. The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway.
Liu B; Fan Z
Oncogene; 2001 Jun; 20(28):3726-34. PubMed ID: 11439335
[TBL] [Abstract][Full Text] [Related]
18. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain.
Huang B; Eberstadt M; Olejniczak ET; Meadows RP; Fesik SW
Nature; 1996 Dec 19-26; 384(6610):638-41. PubMed ID: 8967952
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus RIDbeta subunit contains a tyrosine residue that is critical for RID-mediated receptor internalization and inhibition of Fas- and TRAIL-induced apoptosis.
Lichtenstein DL; Krajcsi P; Esteban DJ; Tollefson AE; Wold WS
J Virol; 2002 Nov; 76(22):11329-42. PubMed ID: 12388693
[TBL] [Abstract][Full Text] [Related]
20. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death.
Stanger BZ; Leder P; Lee TH; Kim E; Seed B
Cell; 1995 May; 81(4):513-23. PubMed ID: 7538908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
